发明授权
- 专利标题： Inhibitor compounds
-
申请号： US17319231申请日： 2021-05-13
-
公开(公告)号： US11897877B2公开(公告)日： 2024-02-13
- 发明人: Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Gaston Andre Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
- 申请人： Cancer Research Technology Limited
- 申请人地址： GB London
- 专利权人： Cancer Research Technology Limited
- 当前专利权人： Cancer Research Technology Limited
- 当前专利权人地址： GB London
- 代理机构： Foley Hoag LLP
- 代理商 David P. Halstead
- 优先权： GB 16017 2012.09.07
- 分案原申请号： US15091887 2016.04.06
- 主分类号： C07D471/04
- IPC分类号： C07D471/04 ; C07D401/14 ; C07D413/14 ; C07D401/04 ; C07D405/04 ; C07D519/00 ; A61K31/519
摘要：
The present invention relates to compounds of formula I
wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
公开/授权文献
- US20220402912A1 INHIBITOR COMPOUNDS 公开/授权日：2022-12-22
信息查询
